  The emergence of COVID-19 has severely compromised the arsenal of antiviral
and antibiotic drugs. Drug discovery is a multistep process with a high failure
rate, high cost and it takes approximately 10-12 years for the development of
new molecules into the clinical candidate. On the other side, drug repurposing
also called old drugs for new uses, is an attractive alternative approach for a
new application of marketed FDA approved or investigational drugs. In the
current pandemic situation raised due to COVID-19, repurposing of existing FDA
approved drugs are emerging as the first line of the treatment. The causative
viral agent of this highly contagious disease and acute respiratory syndrome
coronavirus (SARS-CoV) shares high nucleotide similarity. Therefore, many
existing viral targets are structurally expected to be similar to SARS-CoV and
likely to be inhibited by the same compounds. Here, we selected three viral key
proteins based on their vital role in viral life cycle: ACE2 (helps in entry
into the human host), viral nonstructural proteins RNA-dependent RNA polymerase
(RdRp) NSP12, and NSP16 which helps in replication, and viral latency (invasion
from immunity). The FDA approved drugs chloroquine (CQ), hydroxychloroquine
(HCQ), remdesivir (RDV) and arbidol (ABD) are emerging as promising agents to
combat COVID-19. Our hypothesis behind the docking studies is to determine the
binding affinities of these drugs and identify the key amino acid residues
playing a key role in their mechanism of action. The docking studies were
carried out through Autodock and online COVID-19 docking server. Further
studies on a broad range of FDA approved drugs including few more protein
targets, molecular dynamics studies, in-vitro and in-vivo biological evaluation
are required to identify the combination therapy targeting various stages of
the viral life cycle.
